Combination of tissue and liquid biopsy molecular profiling to detect transformation to small cell lung carcinoma during osimertinib treatment.

ABSTRACT:

Background

Histological transformation of advanced non-small cell lung cancer (NSCLC) to small cell lung cancer (SCLC) is one of the mechanisms of resistance to third-generation tyrosine kinase inhibitors (TKIs), such as osimertinib. This acquired TKI resistance is linked to the high degree of tumor heterogeneity and adaptive cellular signaling pathways, including epidermal growth factor receptor (EGFR)-dependent pathways, observed in NSCLC.

Methods

Here, we investigated a series of paired pre- and post-histological transformation biopsies obtained from three patients initially having a NSCLC with an EGFR ^activating mutation treated with first-generation TKI, who then received osimertinib as second-line after EGFR ^T790M resistance a

SUBMITTER: Vendrell JA 

PROVIDER: S-EPMC7750569 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature